Gladstone Engineered iPSC Neurons Repair Rat Spinal Cords

Researchers at Gladstone Institutes have engineered human induced pluripotent stem cell (iPSC) derived spinal interneurons that survive, integrate and restore breathing function when transplanted into rats with cervical spinal cord injuries. Published in Science Translational Medicine on 5 August 2026, the proof-of-concept study advances a spinal cord injury cell therapy strategy that addresses a persistent unmet need affecting an estimated 15 to 20 million people worldwide.

The Gladstone team, led by first author Lana Zholudeva and senior author Deepak Srivastava, focused on V2a interneurons, a subclass of spinal relay cells central to circuits controlling breathing. Building on nearly a decade of collaborative work, the team spent around 18 months refining a protocol to generate transplantable human V2a interneurons from iPSCs. The engineered cells could be frozen in vials for later thaw and use, an important step toward clinical trial usability. Two months after transplantation into rats with cervical injury, the cells survived, formed connections with adjacent host neurons, and functionally engaged the diaphragm when activated at either the transplant site or the brainstem.

Under normal resting conditions, differences in breathing were subtle. When animals were challenged with low oxygen or high carbon dioxide, most injured untreated rats showed signs of respiratory failure, while roughly three-quarters of the transplanted rats passed the challenges. Before human trials can begin, the team plans larger animal studies, evaluation at later post-injury timepoints, and extension of the approach to arm and hand function, which patients typically identify as their highest recovery priority.

The commercial signal is a growing iPSC-derived cell therapy category taking shape at the intersection of stem cell biology and previously incurable neurological injury. Freeze-thaw compatibility positions the platform for scalable manufacturing. Expect BlueRock Therapeutics (Bayer), Fate Therapeutics, Aspen Neuroscience, InVivo Therapeutics and Kyoto University-linked programmes to sharpen their own iPSC-derived neurological therapy positioning through 2026 and 2027.

For the latest updates and in-depth insights into the world of Life Science, including breakthrough treatments, industry trends, and regulatory news, contact Bailey Osborne today!